Journal
ACTA BIOMATERIALIA
Volume 143, Issue -, Pages 356-371Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2022.02.043
Keywords
Poly(?-amino ester); Anti-inflammatory cytokine; Interleukin-10; Gene therapy; Targeting; VCAM-1; Toxicity; Atherosclerosis
Funding
- CIHR [PJT-162413, 341039]
Ask authors/readers for more resources
This study designed and developed targeted nanoparticles (NP-VHPK) containing IL-10 DNA for atherosclerosis. The results showed that IL-10 can accumulate at atherosclerotic plaques after injection of NP-VHPK, leading to a decrease in local inflammation.
Atherosclerosis progression is a result of chronic and non-resolving inflammation, effective treatments for which still remain to be developed. We designed and developed branched poly(ss-amino ester) nanoparticles (NPs) containing plasmid DNA encoding IL-10, a potent anti-inflammatory cytokine to atherosclerosis. The NPs (NP-VHPK) are functionalized with a targeting peptide (VHPK) specific for VCAM-1, which is overexpressed by endothelial cells at sites of atherosclerotic plaque. The anionic coating affords NPVHPK with significantly lower toxicity than uncoated NPs in both endothelial cells and red blood cells (RBCs). Following injection of NP-VHPK in ApoE -/ - mice, Cy5-labelled IL-10 significantly accumulates in both whole aortas and aortic sinus sections containing plaque compared to injection with a non-targeted control. Furthermore, IL-10 gene delivery results in an attenuation of inflammation locally at the plaque site. NP-VHPK may thus have the potential to reduce the inflammatory component of atherosclerosis in a safe and effective manner.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available